Drug Pipeline & Clinical Trials: Conference Sessions

MGH 50th Annual Psychopharmacology Conference

October 16–18, 2026 · Boston, MA

• LectureClinical Trials of Cannabinoids for Insomnia, Pain, Anxiety, Depression

  Jodi Gilman · Eden Evins

  Summarizes clinical trial findings on cannabinoids for insomnia, pain, anxiety and depression.

  Anxiety DisordersCannabis & CannabinoidsSleep & Insomnia

• LectureNew Treatments for Schizophrenia

  Oliver Freudenreich

  Recently approved and pipeline agents for schizophrenia, including novel mechanisms.

  Muscarinic & Novel AntipsychoticsSchizophrenia & Psychosis

MasterPsych Psychiatry Conference 2026

October 19–22, 2026 · Newport Beach, CA

• LectureNew & Emerging Treatments for SUD

  Ximena Sanchez-Samper

  A three-hour review of newly available and pipeline treatments for substance use disorders.

  Substance Use Disorders

• LectureNew & Emerging Treatments for Substance Use Disorders

  Ximena Sanchez-Samper

  Overview of new and emerging treatments for substance use disorders.

  Substance Use Disorders

• LectureNew & Emerging Treatments for Substance Use D

  Ximena Sanchez-Samper

  Overview of new and emerging treatments for substance use disorders.

  Substance Use Disorders

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• LectureTreatment Frontiers in Autism and Associated Psychopathology: The Role of Glutamate Modulators

  Gagan Joshi

  Explores glutamate-modulating treatments for autism and associated psychiatric conditions.

  Autism & Neurodevelopmental DisordersKetamine & Esketamine

• LectureJames C. Harris, MD, Developmental Neuropsychiatry Forum: Translational Frontiers in Autism: Advancing Discovery from Gene Pathways to Patients

  Rana Elmaghraby · Suma Jacob · Alexandra L. Bey · Pankhuree Vandana · Natasha Marrus · Matthew State · Alison T. Singer

  Matthew State presents how the identification of more than 100 high-confidence autism risk genes is being turned into therapeutic programs, with profound autism as a tractable starting point, while Alison Singer brings the family perspective on genetic testing and trial participation.

  Autism & Neurodevelopmental DisordersNeuroscience & MechanismsPharmacogenomics & Precision Psychiatry

• LectureHarmonizing Outcome Selection and Measurement: Shaping the Future of Youth Mental Health Trials and Practice

  Suneeta Monga

  Addresses harmonizing outcome selection and measurement across youth mental health trials and clinical practice.

  Child & AdolescentMeasurement-Based Care & Diagnosis

• LectureIs It Prevention or Treatment? Methodological Issues Behind the Clinical Update

  David C. Rettew

  Discusses methodological questions in distinguishing prevention from treatment in psychiatric prevention research.

  Child & Adolescent

• PosterThe Safety and Effect of Ecopipam During the First 8 Weeks of Tourette’s Disorder Treatment: A Post-Hoc Analysis

  Kinga K. Tomczak · Tamar C. Katz · John A. Flatt · George B. Karkanias · Stephen P. Wanaski · Timothy M. Cunniff · Donald L. Gilbert

  Post-hoc analysis of the safety and effects of ecopipam over the first 8 weeks of treatment in Tourette's disorder.

  Autism & Neurodevelopmental DisordersChild & Adolescent

See all 23 drug pipeline & clinical trials sessions at this meeting →

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• SymposiumBeyond Abstinence: Measuring What Matters in Cannabis Use Disorder Medication Development

  Christina Brezing · Frances Levin · Margaret Haney · John Mariani

  Argues for moving beyond abstinence as the sole endpoint in cannabis use disorder trials, discussing reduction-based and patient-centered outcome measures.

  Cannabis & CannabinoidsSubstance Use Disorders

• SymposiumNeuromodulation to Treat Addictions: What's Available and What's in the Pipeline

  Manish Jha · Kathleen Brady · Hamed Ekhtiari · Gregory Sahlem · Brian Mickey

  Reviews current and investigational neuromodulation techniques for substance use disorders, including rTMS and focused ultrasound.

  Neuromodulation (ECT, TMS)Substance Use Disorders

• SymposiumSymposium II - Neuromodulation to Treat Addictions: What’s Available and What’s in the Pipeline

  Manish Jha · Kathleen Brady · Hamed Ekhtiari · Gregory Sahlem · Brian Mickey

  Examines current and emerging neuromodulation approaches such as rTMS and focused ultrasound for treating substance use disorders, including personalization and response monitoring.

  Neuromodulation (ECT, TMS)Substance Use Disorders

• Oral abstractAbsolute and Relative Responses of Pharmacological Treatments for Gambling Disorder: A Systematic Review and Meta-Analysis

  Rory Pfund

  Meta-analysis of absolute and relative treatment responses to medications for gambling disorder.

  Substance Use Disorders

• SymposiumSymposium III - Beyond Abstinence: Measuring What Matters in Cannabis Use Disorder Medication Development

  Christina Brezing · Frances Levin · Margaret Haney · John Mariani

  Discusses moving cannabis use disorder trials and clinical care from abstinence-only endpoints toward reduction-based, patient-centered outcome measures.

  Cannabis & CannabinoidsSubstance Use Disorders

See all 7 drug pipeline & clinical trials sessions at this meeting →

39th ECNP Congress

October 10–13, 2026 · Munich, Germany

• SymposiumS01 – Clinical trials across psychiatric disorders: the good, bad and the ugly

  Argyris Stringaris · Christian Otte · Heidi Taipale · Blanca Bolea-Alamanac

  Critical look at psychiatric trial design, generalizability, and digital therapeutics, including who gets excluded from RCTs.

  Digital Psychiatry & AI

• SymposiumS03 – Breaking Hot Topic Symposium – showcasing the timeliest science – Altered immune function in psychiatric disorders and their treatment

  Boris B. Quednow · Sinead King · Jenny Borkent · Anthony Vernon · Cynthia Fu

  Late-breaking findings on immune dysfunction in psychiatry, including the MEMOCYCLINE trial, microbiome-guided treatment, and immune-ageing phenotypes of depression.

  DepressionInflammation & Immunopsychiatry

• PlenaryPL02 – ECNP Neuropsychopharmacology Award Lecture – How will we get novel medicines in psychiatry? Lessons from schizophrenia

  Oliver Howes

  Award lecture drawing lessons from schizophrenia drug development for the broader pipeline of novel psychiatric medicines.

  Schizophrenia & Psychosis

• SymposiumS07 – Engineering mental health: targeted therapies to restore brain and brain-barrier function

  Marianne Mueller · Stefan Liebner · Matthew Campbell · Karen Aboody

  Blood-brain barrier biology as a therapeutic target, plus stem-cell-derived vesicles and focused ultrasound approaches.

  Neuroscience & Mechanisms

• SymposiumMS02 – Proof-of-concept studies showcasing biomarker potential

  Leanne Williams · Daniel Gehrlach

  Stratified precision-medicine trials, including an alpha-2a agonist for the cognitive biotype of depression and phase 2 results for the vasopressin 1b antagonist nelivaptan.

  DepressionPharmacogenomics & Precision Psychiatry

See all 8 drug pipeline & clinical trials sessions at this meeting →

WCP 2026 — 26th World Congress of Psychiatry

September 23–26, 2026 · Stockholm, Sweden

• PlenaryPlenary Session 03: From the Arctic Mutation to a Treatment for Alzheimer's Disease

  Lars Lannfelt

  Traces how discovery of the Arctic APP mutation led to development of amyloid-targeting therapy for Alzheimer's disease.

  Dementia & Cognitive Disorders

• LecturePlenary Session 09 - Closing & Jean Delay Prize Lecture: Myelin and Schizophrenia: From a Better Phenotype to Drug Targets for Treatment

  Peter Falkai

  Award lecture on myelin pathology as a phenotype and treatment target in schizophrenia, closing the congress.

  Neuroscience & MechanismsSchizophrenia & Psychosis

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• CourseAdvanced Psychopharmacology Intensive: Emerging Neurobiologic Targets and Metabolic Pathways Reshaping Psychiatric Treatment

  Brittany Albright · Rakesh Jain · Gregory Mattingly · David Plante

  Half-day ticketed intensive built around four expert-led modules on treatment mechanisms moving beyond monoamines: orexin-based agents, glutamate/dopamine circuit approaches, muscarinic receptor modulation, and GLP-1/bioenergetic pathways.

  GLP-1 & Metabolic PsychiatryMuscarinic & Novel AntipsychoticsNeuroscience & Mechanisms

• SymposiumMasterClass: Seeing the Bigger Picture: How to Evaluate Real-World Evidence Along with RCTs in Psychiatric Treatment Decisions

  Craig Chepke

  Teaches clinicians to weigh real-world study designs against randomized trials, including examples where RWE informed FDA-approved psychiatric therapies.

  Education & Training

• SymposiumLatest Discoveries & Emerging Trends in Psychotic Disorders

  Christoph U. Correll · Ilan Melnick

  Fast-paced review of the year's most significant schizophrenia and psychosis research, with expert commentary and selected poster presenters sharing emerging data.

  Schizophrenia & Psychosis

• SymposiumLatest Discoveries & Emerging Trends in MDD

  Rakesh Jain · Michael Thase

  Year-in-review of depression research spanning neurobiology, trial results, and pharmacologic and non-pharmacologic innovation, with selected poster presenters showcasing new data.

  DepressionNeuroscience & Mechanisms

• SymposiumMasterClass: Translating Orexin Science Into Practice: Psychiatry's Role in Narcolepsy Care

  Craig Chepke · Logan Schneider · Jessica Wright

  Covers orexin-deficiency neurobiology, how to distinguish narcolepsy from psychiatric mimics, and the clinical implications of emerging orexin receptor agonists.

  Neuroscience & MechanismsSleep & Insomnia

See all 7 drug pipeline & clinical trials sessions at this meeting →